Ascendis Pharma Oncology Division A/S: Financial statements 2024
CVR: 41034076
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Ascendis Pharma Oncology Division A/S (CVR 41034076) has filed annual accounts for 2024. In 2024, the company reported a gross profit of EUR -92,475,000 and a net result of EUR -106,375,000 compared with EUR -144,110,203 the year before. Equity in the 2024 report amounted to EUR -391,506,000.
- Gross Profit
- EUR -92,475,000
- Profit/Loss
- EUR -106,375,000
- Equity
- EUR -391,506,000
- Total Assets
- EUR 99,000
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -92.5M EUR | -106.4M EUR | -391.5M EUR | 0 |
| 2023 | - | -140.1M EUR | -144.1M EUR | -285.1M EUR | 0 |
| 2022 | - | -62.4M EUR | -64.9M EUR | -141M EUR | 0 |
| 2021 | - | -46.7M EUR | -48M EUR | -76.1M EUR | 0 |
| 2020 | - | -35.7M EUR | -36.1M EUR | -28.1M EUR | 0 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Ascendis Pharma Oncology Division A/S has published its annual report for 2023. Gross profit came to DKK -140,146,399, and the net result was DKK -144,110,203.
About Ascendis Pharma Oncology Division A/S
Ascendis Pharma Oncology Division A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR -85,226,000 and a net result of EUR -110,131,000 compared with EUR -106,375,000 the year before. Equity in the 2025 report amounted to EUR -501,637,000.
